Pasithea Therapeutics to Call Special Meeting of Stockholders
03 Outubro 2022 - 7:03PM
Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the
“Company”), a biotechnology company focused on the discovery,
research and development of new and effective treatments for
central nervous system (CNS) disorders, today announced that Camac
Partners, LLC, Camac Capital, LLC, Concord IP2 Ltd., Elderhill
Corporation, Leonite Capital LLC, Eric Shahinian, David Delaney,
and Avi Geller (collectively, the “Camac Group”) satisfied the
necessary requirements to call a Special Meeting of Stockholders
(“Special Meeting”).
The Company was notified that the Camac Group demonstrated the
requisite votes on September 28, 2022, and notes that, contrary to
their public statements, the Camac Group’s notifications prior to
that date were invalid.
Pasithea will call a Special Meeting in accordance with the
Company’s bylaws. Additional details about the Special Meeting will
be forthcoming. There is no action required by stockholders.
The Company stated, “During our first year as a public company,
Pasithea has made significant progress towards our mandate to
develop novel and groundbreaking drugs, including achieving
positive preclinical results for our drug discovery programs,
strengthening our team of scientists, expanding our portfolio with
complementary CNS therapies with significant potential, and
enhancing our recently reelected Board of Directors. We are excited
about Pasithea’s future scientific and value creation prospects,
and look forward to continued engagement with our
stockholders.”
McDermott Will & Emery LLP are serving as legal advisor to
the Company and Kingsdale Advisors is serving as an advisor in
connection with the activities of the Camac Group.
About Pasithea Therapeutics Corp.
Pasithea Therapeutics Corporation is a biotechnology company
focused on the discovery, research and development of new and
effective treatments for central nervous system (CNS) disorders.
With an experienced team of experts in the fields of neuroscience
and psychopharmacology, Pasithea is developing new molecular
entities for the treatment of psychiatric and neurological
disorders, including Amyotrophic Lateral Sclerosis (ALS) and
Multiple Sclerosis (MS). Pasithea addresses the needs of patients
currently suffering with mental illness by providing access to IV
ketamine infusions both in clinics and in-home settings.
Forward Looking Statements
This press release contains statements that constitute
“forward-looking statements.” Forward-looking statements are
subject to numerous conditions, many of which are beyond the
control of the Company. While the Company believes these
forward-looking statements are reasonable, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to the Company on the date of this
release. These forward-looking statements are based upon current
estimates and assumptions and are subject to various risks and
uncertainties, including, without limitation, those set forth in
the Company’s filings with the SEC. Thus, actual results could be
materially different. The Company undertakes no obligation to
update these statements whether as a result of new information,
future events or otherwise, after the date of this release, except
as required by law. Such forward-looking statements are subject to
risks (including those set forth in the Company’s Form 10-K for the
fiscal year ended December 31, 2021, as amended, filed with the
U.S. Securities and Exchange Commission) and uncertainties which
could cause actual results to differ from the forward-looking
statements.
Important Additional Information and Where to Find
It
This communication may be deemed solicitation material in
respect of the Special Meeting. The Company plans to file a proxy
statement with the Securities and Exchange Commission, in
connection with the solicitation of proxies for the Special
Meeting. Stockholders are urged to read such proxy statement
(including any amendments or supplements thereto) and any other
relevant documents that the Company files with the SEC carefully in
their entirety when they become available because they will contain
important information.
Certain Information Regarding Participants to the
Solicitation
Pasithea, its directors and certain of its executive officers
and employees are deemed to be participants in a solicitation of
requests not to vote for the Camac Group’s proposal at the Special
Meeting (the “Special Meeting Solicitation”). Information regarding
the identity of these potential participants and their direct or
indirect interests, by security holdings or otherwise, is set forth
in the Consent Revocation Solicitation Statement filed by Pasithea
with the Securities and Exchange Commission on July 28, 2022.
Pasithea Therapeutics Corp. Company Contact
Dr. Tiago Reis MarquesChief Executive OfficerE:
tiago@pasithea.com
Michael Fein Kingsdale Advisors T: 646-651-1641E:
mfein@kingsdaleadvisors.com
Pasithea Therapeutics Corp. Media Contact
Paul Caminiti/Nicholas Leasure ReevemarkT: 212-433-4600 E:
PasitheaTeam@reevemark.com
Pasithea Therapeutics Corp. Investor
Relations
Lisa M. WilsonIn-Site Communications, Inc.T: 212-452-2793E:
lwilson@insitecony.com
Pasithea Therapeutics (NASDAQ:KTTAW)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Pasithea Therapeutics (NASDAQ:KTTAW)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024